



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: Jackowski et al.

INVENTION

: **Biopolymer Marker Indicative Of  
Disease State Having A Molecular  
Weight Of 1350 Daltons**

SERIAL NUMBER

: 09/845,729

FILING DATE

: April 30, 2001

EXAMINER

: Nguyen, Bao Thuy.

GROUP ART UNIT

: 1641

OUR FILE NO.

: 2132.031

CERTIFICATE UNDER 37 CFR 1.8(a)  
I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450 on 11-4-2004

Mail Stop: Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION UNDER 37 CFR § 1.132**

I, George Jackowski, do hereby declare as follows:

1. I am one of the named inventors of the application entitled  
**"Biopolymer Marker Indicative of Disease State Having A  
Molecular Weight of 1350 Daltons"**, having U.S. Application Serial  
No. 09/845,729, filed April 30, 2001.

2. In the Office Action mailed on May 04, 2004, claims 36-40,  
(as originally presented) were rejected under 35 U.S.C. 112, first  
paragraph because the claimed invention allegedly contains subject  
matter which was not described in the specification in such a way

as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims (as currently amended) have been limited to an isolated biopolymer marker having SEQ ID NO:1 (the 1350 dalton marker) useful in methods for determining the presence of the biopolymer marker. The method of the invention as recited in claim 36 involves confirming the presence of the isolated biopolymer marker having SEQ ID NO:1 in the patient sample wherein the presence of the biopolymer marker is indicative of a link to myocardial infarction or renal failure.

3. The data provided in attached Appendix A was originally filed in Applicant's application no. 09/846,330, now Pub. No. U.S. 2002/016042C, both applications were filed on April 30, 2001. The data further clarifies the identification of SEQ ID NO: 1 in serum samples of patients being evidentiary of a renal failure or myocardial infarction sampled from patients suffering from a variety of disease states, see pages A3 to A4 of Appendix A.


4. This declaration (including the attached Appendix A) is provided in order to show data obtained from a clinical trial involving over 500 patients suffering from a variety of disease states, see page 32 lines 9 to 15 of Pub. No. U.S. 2002/0160420. The patient specific samples and data are used to formulate a library of proteomic materials having characteristics identifiable with both normal and abnormal physiological conditions or predictive hallmarks thereof. The data on pages A3 to A4 of Appendix A indicates the patients from which the isolated

biopolymer marker consisting of SEQ ID NO:1 (the 1350 dalton marker) was confirmed are linked to myocardial infarction or renal failure. This Appendix A does not represent results obtained from additional experimentation. This data was obtained in the original experiments performed at the time of the invention.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

Nov 4 2004

Date

  
\_\_\_\_\_  
George Jackowski

\\Ns2\client files\2100-2199\2132 -Syn-X\2132\_000031 - Marker 1350\Amendments\2132\_031.132.wpd

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 07	M	65	MI, Hx of arthritis,	MI	1020	Alpha Fibrinogen	(G)DFLAEGGGVR(G)
HNS-SJ28				MI	1020	Alpha Fibrinogen	(G)DFLAEGGGVR(G)
HNS-SJ33				MI	1020	Alpha Fibrinogen	(G)DFLAEGGGVR(G)
SJ CON 06	F	77		MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
SJ CON 17	M	58	MI	MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
SJ CON 19	M	52	Acute MI, SK???	MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
SJ CON 21	M	65	Non-Q wave MI, Hx HTN	MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
HNS-SJ28				MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
SJ CON 05	F	67	Rectal bleed, Asthma, NIDDM	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAVAA(-)
SJ CON 06	F	77	MI, NIDDM	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAVAA(-)
TWH-039	M	62	A.fib, Diabetes, smoker, HTN	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAVAA(-)
184-988	M	73		Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAVAA(-)
TWH-039	M	62	A.fib, Diabetes, smoker, HTN	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAVAA(-)
184-988	M	82		Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAVAA(-)
SJ CON 01	M	82		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 05	F	67		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 06	F	77		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 09	M	80		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 07	M	65		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 10	F	50		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 14	F	65		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 11	M	68	Unstable angina, hemodialysis	Renal failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 13	F	80	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 06	F	77		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 07	M	65	GE (gastroesophageal) reflux	MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 10	F	50	Inferior MI, Hiatal Hernia	MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 14	F	65	MI, NIDDM	MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 17	M	58		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 19	M	52		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 21	M	65		MI	1211	Complement C3f	(H)RIHWESASLL(R)
HNS-SJ22				MI	1211	Complement C3f	(H)RIHWESASLL(R)
HNS-SJ28				MI	1211	Complement C3f	(H)RIHWESASLL(R)
HNS-SJ33				MI	1211	Complement C3f	(H)RIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used IPA	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
23604 - KKB	M	61	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 06	F	77		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 07	M	65		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 10	F	50	Hemodialysis	MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 14	F	65	hemodialysis	MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 17	M	58		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 19	M	52		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 21	M	65		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
HNS-SJ22				MI	1348	Complement C3f	(T)HRIHWESASLL(R)
HNS-SJ28				MI	1348	Complement C3f	(T)HRIHWESASLL(R)
HNS-SJ33				MI	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used IPA	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 01	M	82		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 05	F	67		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 06	F	77		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 06	F	77		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 09	M	80		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 07	M	65		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 07	M	65		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 10	F	50		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 10	F	50		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 14	F	65		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 14	F	65		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 17	M	58		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 19	M	52		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 21	M	65		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ22				MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ28				MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ33				MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1350	Alpha Fibrinogen	(D)ESDFLAEGGGVR(G)
SJ CON 11	M	68	Unstable angina, hemodialysis	Renal failure	1350	Alpha Fibrinogen	(D)ESDFLAEGGGVR(G)
SJ CON 13	F	80	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1350	Alpha Fibrinogen	(D)ESDFLAEGGGVR(G)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23421 - FB	M	59	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
22813 - CL	F	66	STAGE 4	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23130 - ER	M	51	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23105 - FC	M	64	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23116 - FC	M	59	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
20414 - EYG	F	76	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23130 - ER	M	51	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23134 - FC	M	62	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
20102 - EAB	M	70	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
SJ CON 06	F	77		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 07	M	65		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 10	F	50		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 14	F	65		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 17	M	58		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 19	M	52		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 21	M	65		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
HNS-SJ22				MI	1449	Complement C3f	(I)THRIHWESASLL(R)
HNS-SJ28				MI	1449	Complement C3f	(I)THRIHWESASLL(R)
HNS-SJ33				MI	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used IPA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
22703 - MMS	F	67	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 01	M	82	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 05	F	67		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 06	F	77		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 09	M	80		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 07	M	65		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 10	F	50		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 14	F	65		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 11	M	68	Unstable angina, hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 13	F	80	Rapid atrial Fib. Prior Hx CAN hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-12	F	44	ICH	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 07	M	65		MI	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
SJ CON 10	F	50		MI	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
HNS-SJ22				MI	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
SJ CON 01	M	82		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 05	F	67		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 06	F	77		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 09	M	80		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)



# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 07	M	65		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 10	F	50		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 14	F	65		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 11	M	68	Unstable angina, hemodialysis	Renal failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 13	F	80	Rapid atrial Fib. Prior Hx CAN hemodialysis	Renal failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 10	F	50		MI	1525	Serum Amyloid A	(D)PNHFRPAGLPEKY(-)
HNS-SJ22				MI	1525	Serum Amyloid A	(D)PNHFRPAGLPEKY(-)
HNS-SJ28				MI	1525	Serum Amyloid A	(D)PNHFRPAGLPEKY(-)
HNS-SJ22				MI	1536	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
SJ CON 06	F	77		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 19	M	52		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 21	M	65		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
HNS-SJ22				MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
HNS-SJ33				MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 06	F	77		MI	1616	Complement C3f	(K)ITHRIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 07	M	65		MI	1616	Complement C3f	
SJ CON 10	F	50		MI	1616	Complement C3f	
SJ CON 14	F	65		MI	1616	Complement C3f	
SJ CON 17	M	58		MI	1616	Complement C3f	
SJ CON 19	M	52		MI	1616	Complement C3f	
SJ CON 21	M	65		MI	1616	Complement C3f	
HNS-SJ22				MI	1616	Complement C3f	
HNS-SJ28				MI	1616	Complement C3f	
HNS-SJ33				MI	1616	Complement C3f	
SJ CON 06	F	77		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used IPA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
2206 - MM	F	75	STAGE 4	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 01	M	82	NIDDM, CHF, Hypothalemia??	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 01	M	82	patient died of CA Dec. 22/98	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 05	F	67	hemodialysis	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 06	F	77	hemodialysis	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 06	F	77		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 09	M	80	NIDDM, HTN, Rio?? Angina	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-002	M	81		Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH -009	M	76	Aphasia, Rt hemiparalysis,	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used IPA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
20206 - MM	F	75	STAGE 4	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-002	M	81		Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH -009	M	76	Aphasia, Rt hemiparalysis,	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-002				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH -009				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH-024				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH-039				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
743-450				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
184-988				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
734-989				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
SJ CON 01	M	82		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 06	F	77		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 06	F	77		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 09	M	80	Hx of prostate CA, hemodialysis	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-002	M	81		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH -009	M	76	Complete hemianopia, smoker	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-024	M	63	Stroke, PM Hx, NIDDM, incr BP	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-039	M	62		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
184-988	M	73	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
734-989	M	65	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 19	M	52		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 21	M	65		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
HNS-SJ22				MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
HNS-SJ28				MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
HNS-SJ33				MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used tPA	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
20102 - EAB	M	70	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-002				Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-009			Complete hemianopia, smoker	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-024	M	63	Stroke, PM Hx, NIDDM, incr BP	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-039				Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
184-988	M	73	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
734-989	M	65	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1896	Complement C4A	(R)NGFKSHALQLNNRQIR(G)
SJ CON 17	M	58		MI	1896	Complement C4A	(R)NGFKSHALQLNNRQIR(G)
HNS-SJ22				MI	1896	Complement C4A	(R)NGFKSHALQLNNRQIR(G)
TWH-002				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
TWH-009				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
TWH-024				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
TWH-039				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
743-450				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
184-988				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
734-989				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
SJ CON 01	M	82		Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
SJ CON 06	F	77		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 06	F	77		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 09	M	80		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-002	M	81		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-009	M	76		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-024	M	63		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-039	M	62		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
184-988	M	73		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
734-989	M	65		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 07	M	65		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 10	F	50		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 14	F	65		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 17	M	58		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 19	M	52		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 21	M	65		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
HNS-SJ22				MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
HNS-SJ28				MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
HNS-SJ33				MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23604 - KKB	M	61	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23707 - KL	F	65	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22703 - MMS	F	67	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20206 - MM	F	75	STAGE 4	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22103 - GM	F	77	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
21813 - GR	F	65	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23402 - HM	M	67	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20208 - HIF	M	79	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22803 - HB	M	60	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23616 - JGK	M	43	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23421 - FB	M	59	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22813 - CL	F	66	STAGE 4	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23130 - ER	M	51	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23105 - FC	M	64	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23116 - FC	M	59	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20414 - EYG	F	76	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23130 - ER	M	51	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23134 - FC	M	62	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20102 - EAB	M	70	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-002				CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH -009				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-024				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-039				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
184-988				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
734-989				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23604 - KKB	M	61	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23707 - KL	F	65	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22703 - MMS	F	67	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20206 - MM	F	75	STAGE 4	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22103 - GM	F	77	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
21813 - GR	F	65	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23008 - GFB	M	67	STAGE3 - DEAD	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23402 - HM	M	67	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20208 - HIF	M	79	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22803 - HB	M	60	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23616 - JGK	M	43	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20803 - EW	M	45	Acute MI - STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23421 - FB	M	59	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22813 - CL	F	66	STAGE 4	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23130 - ER	M	51	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23105 - FC	M	64	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23116 - FC	M	59	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20414 - EYG	F	76	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23130 - ER	M	51	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR

# APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
23134 - FC	M	62	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20102 - EAB	M	70	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
3111898	M	?	Insulin Resistance	Insulin Resistance	2267	Apolipoprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
112698	F	?	Insulin Resistance	Insulin Resistance	2267	Apolipoprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
5124698	F	?	Insulin Resistance	Insulin Resistance	2267	Apolipoprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
3111898	M	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
42698	M	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
112698	F	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
6101600	F	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
5124698	F	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
3111898	M	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
42698	M	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
112698	F	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
6101600	F	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
5124698	F	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)